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Abstract
The allylation of indirubin produced the expected indolic N'-allylindirubin and N,N'-diallylindirubin
derivatives in moderate yields, together with the corresponding N-substituted isatin products. At higher
temperatures, the base-initiated reaction with allylic halides yielded spiroindolinepyrido[1,2a]indolediones in a one-pot cascade reaction sequence with yields of up to 70%. These readily accessed,
new spiro compounds represent the first reported examples of indirubin participating in cascade reactions.
Preliminary in vitro biological testing of some of the products indicated promising activity against some
cancer cell lines and against Plasmodium falciparum for two spiro derivatives. Computational methods
were used to gain a greater understanding of the UV/Vis spectroscopic data for the N'-substituted and
N,N'-disubstituted indirubin derivatives.
1. Introduction
The search for new molecular entities, especially easily accessible complex heterocycles, is of significant
interest in the exploration of new bioactive compounds and in materials chemistry. Often, cascade
reactions are used to realize such synthetic targets starting with small molecules and utilizing them in
complex multistep reactions. Our recent contributions to this field have focused on a notable variation to
this strategy in that we started with a larger, but abundant and cheap molecule, the dye indigo 1 (Figure
1). Indigo afforded a unique opportunity in providing an advanced starting material for the potential rapid
synthesis of the diindolic system of natural product analogs. To this end, we recently reported the first
cascade reactions of indigo via base-initiated allylation and propargylation, producing unexpected
polyheterocyclic compounds (Figure 1) in multistep reactions. This surprising result revealed a new arena
in the previously unreported chemistry of indigo, allowing access to unique, relatively complex
heterocycles in one pot.1-3
The structural isomers of indigo 1, indirubin 2 and isoindigo 3 (Figure 2), are known,4 but knowledge of
their chemistry is still limited. Indirubin is the most well studied due to the reported biological activity of
derivatives, known to suppress the metastatic ability of human head and neck cancer cells5 and to reduce
the invasion of glioma cells both in vitro and in vivo.6 Further examples include inhibition of cyclindependent kinases7 and glycogen synthase kinase-3, the latter being linked to Alzheimer’s disease.8
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Figure 1: Selected examples of heterocycles produced via the cascade
reactions of indigo using either allyl bromide or propargyl bromide and base.

Indirubin also inhibits intersegmental vessel growth and induces cellular apoptosis in an in vivo zebrafish
model9 while other indirubin derivatives or analogues,10 including N-glycosides, show antiproliferative
activity against a number of human cancer cell lines.11,12 Other effects of indirubin or derivatives include
anti-protozoal activity13 as well as inhibition of lipoxygenase.14 Isoindigo, its derivatives and analogues,
also display a suite of useful biological effects including anti-cancer15,16 and anti- protozoal activity.17
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Figure 2. Indigo 1 and its structural isomers indirubin 2 and isoindigo 3.

Equally important is the basic chemistry of indirubin, including reaction at the carbonyl group, e.g. oxime
formation,18 which often leads to an increase in biological activity, attack by Grignard reagents19 and
substitution reactions at the amide functionality.20 An isoindigo derivative has also been shown to provide
an advanced starting template for total synthesis, e.g. the use of the 2,2'-double bond in N-tosylisoindigo
as a dienophile in a key early Diels˗Alder reaction to build up molecular complexity with stereochemical
control in synthetic studies toward the anti-leukemic marine alkaloid communesin F.21
Therefore, given the recent understanding of cascade reactions of indigo 1, we investigated the possibility
of analogous cascade reactions of indirubin 2 and their potential to generate new heterocycles in one pot.
These results are disclosed in this paper together with some initial in vitro antiplasmodial,
antimycobacterial, and cell-based anticancer activity data.

2. Results and Discussion
2.1. Synthesis and Product Identification
Initial reactions with indirubin were performed as per the allylation of indigo.1 In a typical reaction, a
solution of indirubin in DMF with caesium carbonate was sonicated for 30 min to aid solubility and anion
formation. The reaction was heated to 70 °C followed by the addition of the allyl bromide and heated for
16 hours. The outcomes of these reactions are summarized in Scheme 1. The use of the allyl bromide
gave a 10% yield of the known22 oxidative cleavage product N-allylisatin (Type A), together with the
pink mono oxindolic N-allylated indirubin 9 (Type B) and the deep blue diallylindirubin 14 (Type C) in
24% and 19% yields, respectively. This initial reaction indicated that indirubin is significantly less
reactive than the corresponding indigo. The use of substituted allyl bromides continued the trend with the
pink mono allylated derivatives (Type B) being produced in yields from 20-49% in 16 hour reactions
(entries 1-4), with an extended 20 hour reaction required to produce the N'-cinnamylindirubin 13 (21%).
The diallylated indirubins (Type C) were also produced in the same reactions in yields of 3-30% although
these ratios are somewhat misleading due to the variable stability of the Type C compounds under the
reaction conditions, e.g. with cinnamyl bromide and a 4 hour reaction time the N,N'-dicinnamylindirubin
18 was isolated in an 11% yield (entry 6), but in a 20 hour reaction, the major outcome was the Type B
N'-cinnamylindirubin 13. The instability of Type C molecules presumably to arises from removal of the
stabilizing H···OC H-bond once all NH functionality is substituted. Also, in contrast to the that observed
with indigo,1,2 no final O-allylated indirubin derivatives were observed. Further, no indirubin remained at
the end of the reactions suggesting that compared to indigo, initial alkylation is easier (to the non-Hbonded N'H) but the resulting molecules are less reactive than indigo to subsequent cascade reactions.
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Figure 3. The Z-isomer of indirubin (2), N'-allylindirubin (9) and, N,N'-diallylindirubin (14): Illustrated on 9 – the
calculated angles are indicated by dashed lines, distances are indicated by arrows. NH1--O=C2' distances and angles as well as
ArH4'--O=C3 distances and angles and the corresponding 1H NMR shifts of indirubin (2), N'-allylindirubin (9) and N,N'diallylindirubin (14). Calculated data are obtained using Hartree-Fock theory after optimization at the 6-31G* level.

The 1H NMR spectrum of 9 indicated peaks at 4.46 ppm (d, J = 5.5 Hz), 5.22 ppm (s), 5.25 ppm (d, J =
5.0 Hz) and 5.86-5.92 ppm (m), assigned to a single N-allyl substituent, as quantified by its relative
integration to the indirubin aromatic protons. A single signal at 10.53 ppm was assigned to the NH,
positioned downfield due to its H-bonding with the indirubin carbonyl. This also indicated that the allyl
substituent was positioned on the N'-atom. Measurement of the HRMS (ESI) gave 303.1143, indicative of
a molecular formula of C19H15N2O2, providing evidence for the presence of only a single allyl moiety.
Analysis of the 1H NMR spectra of 14 showed an absence of a peak in the ~10.5 ppm region suggesting
the loss of an NH moiety. The integration of the peaks assigned to the allyl substituent (e.g. 4.43 ppm
(2H) and 4.82 ppm (2H) relative to the total number of peaks assigned to the indirubin H-atoms indicated
a ratio of indirubin:allyl substituents to be 1:2. Further, the measured HRMS (ESI) of 14 relayed a
molecular formula of C22H19N2O2. In other base-induced N-alkylation reactions of indirubin by simple
alkyl halides, preferential alkylation of the oxindolic nitrogen was also observed.23
In order to assess whether either the mono- or di-allylated products had undergone isomerization during
the reaction process to form the 2,3'-E products (with a syn disposition of the carbonyl groups), and to
support the product identifications, we undertook a series of computational experiments to characterize
the monallylindirubin 9 and the diallylindirubin 14.
Calculated distances (NH1···O=C2') and angles (N-H···O) between the amine group and the proximal
carbonyl oxygen in indirubin (2) and its N'-allylated (9) and N,N'-diallylated (14) derivatives highlight the
hydrogen bond character (Figure 3). Additionally, the distance (H4···O=C3) and angle (C-H···O)
between the aromatic hydrogen H4' and the proximal carbonyl group are in accordance with the
remarkable 1H NMR downfield shift of the aromatic hydrogen H4' and indicate the strong interaction
(“H-bond”) of H4' with the proximal carbonyl group.
The initial reaction product results at 70 °C clearly indicated a lower reactivity of indirubin to subsequent
cyclisation. Therefore, in an attempt to force potential cascade reactions, the reactions were repeated at
110 °C (Scheme 1, entries 7-12). This gave rise to the new spiroindolinepyrido[1,2-a]indoledione
heterocycles of the type D in up to 70% yield in the case of allyl bromide (entry 7), arising from the
introduction of three allylic moieties; at 70 °C, 19 (see also Figure 4) was isolated in only 2% yield. The
1

H NMR of 19 showed a ddd centred at 2.06 ppm with J = 18.3, 5.3 and 1.8 Hz, assigned to the sp2

alkenyl H8'a - the corresponding H8'b was assigned to the dt (J = 18.3, 1.8 Hz) at 3.00 ppm. The signals
assigned to H6' and H7' are contained within multiplets at 7.00 - 7.06 and 5.02 - 5.41 ppm respectively.
The signal in the 13C NMR spectra at 48.0 ppm was assigned to the spiro C3, and the C2 amide carbonyl
was assigned to the peak at 175.6 ppm whereas the peak at 199.1 ppm was attributed to the C10' carbonyl.
Confirmation of the molecular formula of 19 was provided by analysis of the HR ESI mass spectrum
which indicated an exact mass of 383.1751, assigned to the [M + H]+ ion of C25H23N2O2.
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Scheme 1. The products of the reactions of indirubin 2 with a series of allyl bromides: Type A - isatin derivatives (4 - 8), Type
B - N'-substituted indirubin derivatives (9 - 13), Type C - N,N'-disubstituted indirubin derivatives (14 - 18) and Type D spiroindolinepyrido[1,2-a]indoledione derivatives (19 - 22). † Note: C-allyl substituent is not crotyl but has rearranged – see
Figure 4 for details of structure. Trace indicates detected by TLC analysis at the completion of the reaction. # 3 Å sieves were
additionally added to procedure B reactions.

Analysis of the 1H NMR spectra of 21 revealed a dd at 5.03 ppm, assigned to the H7' olefin and multiplets
at 7.08-7.16 and 3.40-3.47 ppm which were assigned to H6' and H8' within these peaks respectively
(Figure 4). The terminal methyl group of the N-1-butenyl substituent was assigned to the doublet at 1.72
ppm (J = 7.3 Hz) whereas the methyl substituent of the N-2-butenyl substituent was assigned to the
doublet at 0.52 ppm (J = 8.0 Hz). The terminal olefinic methylene of this substituent was assigned to the
doublet of doublets at 4.64 ppm (J = 10.0, 1.8 Hz) and 4.86 ppm (J = 17.0, 2.1 Hz) with the former in a
cis orientation to the adjacent CH (multiplet at 5.72-5.89 ppm) and the latter in the relative trans

orientation. These assignments indicated the presence of the C-methylallyl substituent, possibly formed
by a rearrangement process after O-alkylation as discussed in the mechanistic section.
The structures of the spiroindolinepyrido[1,2-a]indolediones 19, 20 and 21 were confirmed by single
crystal X-ray crystallographic analysis, corroborating the C-allylic substituents and relative
stereochemistry with the syn disposition of the C-allylic substituent and the 3,8' C-C bond in each case
(Figure 4).

Figure 4. Crystal structures of the spiroindolinepyrido[1,2-a]indolediones 19, 20 and 21.

There are reports24,25 of the synthesis of molecules with the same spiro heterocyclic skeleton to that in 1922, however these arose from reaction of skatole with 2-methylindole, followed by acylation in polar
solvents – subsequent examination of the by-products revealed a spiro-type system, however, there was
limited spectral evidence to support the proposed structures.
The yields for the spiroindolinepyrido[1,2-a]indoledione systems from indirubin decrease with
substitution of the allyl bromide, e.g. the yield drops to 37% with the additional methyl substituent at C2
of the allyl moiety (entry 8) and down to 13% with the use of cinnamyl bromide (entry 12), this latter
reaction requiring significantly longer reaction times (24 h) to achieve even this yield. With a very bulky
terminal gem-dimethyl group in the allylic bromide, no spiro-cyclization was observed. This trend is
likely to arise from the steric impedance of the orthogonal spiro scaffold blocking the approach of the
substituted allyl units during the installation of the C-allyl substituent (see Section 2.2 Mechanistic
Proposals). Although the spiroindolinepyrido[1,2-a]indoledione 19, arising from addition of allyl
bromide, was also observed in the reaction performed at 70 °C in a 2% yield (entry 1), no other examples
were detected in reactions at this temperature (entries 2-6), probably indicative of the extra bulk of the
substituted allyl moieties sterically impeding the spiro cyclisation. Further, in the 110 °C reactions
(entries 7-12), there was no evidence of the presence of Type C products with Type B compounds

probably reacting further at the higher temperature to the Type D products. The N-allylisatins were only
detected in the 110 °C reactions in the case of the cinnamyl moiety (9%) at 6 h (entry 11). It is likely that
the bulky cinnamyl unit lead to a slower reaction, allowing time for the oxidative cleavage to occur. The
longer reaction times at higher temperatures probably resulted in further degradation in the reaction
mixture.
Along with these major products, minor fragmentation products were isolated including the anthranilate
esters allyl 2-(allylamino)benzoate and 2-methylallyl 2-((2-methylallyl)amino)benzoate in very low yield
from the respective allylation reactions at 110 °C and 70 °C. Structural elucidations of these esters arose
from analysis of spectral data, with a diagnostic absorption band for the ester carbonyl group being
apparent at 1673 cm-1 for the former and at 1682 cm-1 for the latter.
For comparison purposes with the indigo substrate,3 reaction of propargyl bromide with indirubin in the
presence of base at 70 °C for 16 hours only yielded N,N'-dipropargylindirubin 23 in low yield (13%) plus
some (8%) of the isatin-derived anthranilate ester, prop-2-yn-1-yl 2-(prop-2-yn-1-ylamino)benzoate.
2.2. Mechanistic Proposals
The proposed mechanism for the 70 °C reactions proceeds with N-allylation on the oxindole ring
producing the Type B compounds with a simple second allylation affording the Type C compounds
(Scheme 2). In the 110 °C reactions, the diallylindirubin (Type C) upon O-protonation (tentatively with
the weakly acidic bicarbonate ion as the proton source) and subsequent electron redistribution yields the
intermediate ion X, which under base-catalysed conditions, undergoes cyclisation to form the spiro
moiety (intermediate Y), with the C3' position activated by the conjugated protonation nitrogen atom.
Subsequent O-allylation would generate the intermediate Z, a molecule not yet isolated from this
reaction, as it is presumably converted rapidly to the isolated Type D spiro compounds. A number of
possibilities exist for the mechanism converting Z to Type D compounds: a 1,3-Claisen rearrangement
would yield the observed outcome for spirocycles 19 and 20, but not for 21 and 22. Similarly, a route via
enolate anion formation followed by a direct C9a allylation process, while satisfactory for most examples,
does not explain outcome 21. A possible unifying mechanism that explains all results is a thermallyinduced homolytic cleavage radical cleavage of the allyloxy group in Z to produce two highly stabilised
radical species, which could then react through attack at C9a to afford 21.2 With the comparable cinnamyl
product 22 it is likely that steric factors mitigate against the cinnamyl radical at the carbon bearing the
phenyl group.
The

13

C NMR spectra for these heterocycles showed no duplication in peaks, consistent with the

formation of a single enantiomeric pair out of the four possible diastereomers. The proposed mechanism
is in accordance with this observation with the initial cyclisation to form the spiro atom likely to produce
both possible stereoisomers as approach from either face would be equal. The generation of the second
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Scheme 2. Proposed mechanism towards the formation of the spiroindolinepyrido[1,2-a]indolediones 19 - 22.

stereogenic atom occurs during the final rearrangement step and here, there is a clear facial discrimination
with the approach of the allyl unit (probably an allylic radical species) from the less hindered carbonyl
side. The higher temperature of 110 °C is required to drive the reaction through to the Type D spiro
compounds, while at 70 °C, N-monoallylation and N,N'-diallyation products predominate. In a separate
experiment, reaction of the N-monoallylated indirubin (9) with excess allyl bromide at 110 °C for 20 h,
only produced a complex mixture with no indication of the spiroindolinepyridoindole heterocycle (14),
presumably due to further reaction of this compound under the conditions. We observed that N,N'disubstituted indirubins were not stable in solution at room temperature under light exposure. When N,N'diallylindirubin was kept in dichloromethane for several days, its colour gradually changed from dark
blue to reddish-yellow. It is known that indigo is stable against photoinduced Z -> E isomerisation due to
its stabilizing NH hydrogen bonding, but substitutions on both nitrogens results in a loss of hydrogen
bonding and leads to phototropic behaviour.26 The same loss of H-bonding may be the reason for the low
stability of the disubstituted indirubins (c.f. Fig. 3): the Z configuration of indirubin and its N'-substituted
derivatives exhibit stabilizing NH-mediated hydrogen bonds and are therefore inert against Z to E
isomerisation, while this is not the case for the disubstituted indirubins and photoinduced Z to E
isomerization occurs.
The formation of the isatin based products can be rationalised in terms of oxidative cleavage with
adventitious oxygen.22 Subsequent nucleophilic attack by allyl alcohol (formed from the bromide in the
presence of carbonate) on the isatin C2-carbonyl and then addition to the C3 carbonyl, followed by
fragmentation with loss of carbon dioxide and propene would give the minor anthranilate ester observed.
2.3. Colour Properties
Indirubin (2) as well as its N'-substituted derivatives (9-13) are red compounds with UV/Vis absorption
maxima of about 536 nm and 533 nm in methanol whereas the N,N'-disubstituted derivatives (14-18)

without an NH…OC hydrogen bond are blue and have a UV/Vis absorption maximum of about 575 nm
in methanol. Selected data is given in Table 1.
Calculated UV/Vis absorption maxima differ significantly from the experimental values but the increase
in λmax from the N'-allylated to the N,N'-diallylated indirubin is predicted correctly with the Hartree Fock
and DFT methodology. However, the calculated wavelengths using B3LYP theory are closer to the
experimental wavelengths in comparison to Hartree-Fock theory. Taking into account the solvent effect,
which leads to a bathochromic shift of the absorption maximum wavelengths the more polar the solvent
used, the B3LYP results are acceptable as the calculated values are in vacuo (Table 2). In contrast to the
indirubins, the spiroindolinepyrido[1,2-a]indoledione (19) is yellow, reflecting the absence of the 2,3'double bond and the consequent decrease in conjugation. In order to examine this further, the calculated
UV/Vis absorption spectra in vacuo and experimentally obtained UV/Vis spectra of 19 were compared
(Table 1). Again, density functional theory (B3LYP) correctly predicted the observed large decrease in
λmax for 19 compared with 14. The predictive power of DFT has been well established by Jacquemin et al
for indirubin, isoindigo and derivatives25,26 including the observation that better fits between theory and
experiment occur when bulk solvent effects are included in the calculations. Further investigations are
required to more fully examine this with compounds 9 and 14.
The loss of a hydrogen bond should lead in theory to an increased energy difference between the ground
state and the excited state and therefore to an UV/Vis absorption maximum at lower wavelengths.29,30
However, the opposite is observed with the calculated values (2 to 9). This bathochromic shift can be
explained by referring to the ‘cross-conjugated’ system (‘H-chromophore’), which was found to be an
important feature to explain (although other explanations have been proposed31), the colour of indigoid
molecules.32,33 It consists of a C=C double bond substituted with two electron donor groups (EDGs; in an
anti configuration to each other) and two electron withdrawing groups (EWGs; in an anti configuration to
each other). In indirubin and the N-allylated derivatives such a chromophore is present with the two
carbonyl moieties as EWGs and an amino group and a fused aryl ring as electron donor groups.
Calculations of the UV/Vis absorption maxima using B3LYP (after optimization at the 6-31G* level) on
2, 9 and 14, as well as cut down oxopyrrolidinylideneindolinone theoretical model systems lacking one
fused benzene ring, supported the significance of the H-chromophore in determining the colour of these
systems (see Supplementary Information for the structures of the model systems and the full results).
2.4. Biological Activity
As indirubin and its derivatives are known to be active against various cancer cell lines, we screened our
derivatives against a small number of cancer cell lines, namely small cell lung cancer (NCI-H187), KBoral cavity cancer and MCF-7 breast cancer, as well as testing for in vitro anti-TB (Mycobacterium
tuberculosis, H37Ra strain) and anti-plasmodial (Plasmodium falciparum, K1 strain) activity. The results
are summarized in Table 2.

Table 1. Summary of experimentally obtained UV/Vis absorption maxima (spectra are measured in methanol) and
calculated UV/Vis absorption maxima (spectra are calculated in vacuo) using B3LYP and Hartree Fock theory after
optimization at the 6-31G* level. The numbers in between rows are the differences between absorption maxima for the
respective compound pairs.
Colour UV/Vis absorption maxima (λmax, nm)
Experimental
Compound
indirubin (2)

(solid)

(CH2Cl2)

red

536

Hartree Fock
474
-3

N'-allylindirubin (9)

red

533

blue

577

spiroindolinepyrido[1,2-a]indoledione (19)

yellow

426

+6
317

+22
512

-151

311

+16
490

+44
N,N'-diallylindirubin (14)

B3LYP

+18
335

-127
385

0
335

The isatin derivatives 4 and 5 showed modest, cytotoxic activity against the small cell lung cancer cell
line but not against the other tested cancer cell lines, nor the mycobacterial or plasmodial strains. The N'substituted and N,N'-disubstituted indirubins show activities against the lung cancer cell line with the
most potent compound being the mono diamethylallyl substituted derivative 12, with an IC50 value of
0.66 μg/mL (2.0 µM) comparable to the positive controls ellipticine (1.47 μg/mL; 5.97 µM) and
doxorubicin (0.077 μg/mL; 0.147 µM). A little surprisingly, compound 12 was inactive against the other
two cancer cell lines. The most promising compound in the N,N'-disubstituted indirubin series was the 2methylallyl derivative 15, with activity against all three cancer cell lines, and being somewhat better than
the positive controls against the rather refractory MCF-7 cell line; modest anti-TB activity in vitro was
also apparent with this compound, while the disubstituted indirubin 16 was active in the anti-plasmodial
assay. Although indirubin derivatives have been shown13 to inhibit the apicomplexan protozoal parasite
Toxoplasma gondii, to the best of our knowledge anti-plasmodial activity of N,N'-disubstituted indirubins
involving the apicomplexan Plasmodium falciparum has not been reported previously. However,
derivatives with the isomeric isoindigo skeleton do show such inhibitory activity against P. falciparum.17
Of the four spiroindolinepyrido[1,2-a]indolediones tested, anti-proliferative activity was seen only with
compounds 19 and 22, although no clear SAR outcomes can be drawn from this limited series. Promising
anti-plasmodial activity in the low micromolar range was also seen with 19 and 22, and these compounds
could serve as useful new leads for potential antimalarial drug development, with the incorporation of a
spiro element in the framework of particular interest.34,35
3. Conclusions
We report here for the first time cascade reactions of indirubin through the reaction with allylic bromides
in the presence of base. The initial reaction can be controlled to produce the pink-red N-monoallylated
products, but the subsequent synthesis of the deep blue N,N'-diallylated indirubin was less successful due
to the instability of the products. The cascade process begins when the reaction is heated to 110 °C –
these are higher temperatures to induce the ongoing reaction process when compared to the reactions of

Table 2. Anti-cancer, anti-tubercular, and anti-plasmodial activity of compounds against three different cancer cell lines small
cell lung cancer (NCI-H187), KB-oral cavity and MCF 7 breast cancer, all tested using a resazurin microplate assay (REMA),
and an anti-TB (Mycobacterium tuberculosis, H37Ra strain), tested using a green fluorescent protein microplate assay
(GFPMA); anti-plasmodial activity (Plasmodium falciparum, K1 strain), tested using a microculture radioisotope technique.
Oral
Anti-TB Anti-Plasmodial
Lung Cancer
Breast Cancer
Cancer
IC50
IC50
IC50 μg/mL
IC50 μg/mL
IC50 μg/mL
μg/mL
(µM)
(µM)
μM
(µM)
(µM)
4
9.37
(50.1)
5
2.9
(14.4)
9
5.86
(19.4)
10
12.50
(39.6)
11
7.52
(23.8)
12
0.66
(2.0)
13
33.78
43.37
(89.4)
(114.7)
15
6.46
12.37
3.94
50.00
(17.5)
(33.4)
(10.6)
16
4.82
20.69
(13.0)
(55.9)
17
20.72
15.19
(52.1)
(38.1)
23
33.15
29.98
(98.1)
(88.7)
19
9.82
18.94
3.69
(24.8)
(47.8)
(9.3)
20
21

-

-

Ellipticine

7.94
(18.7)
1.47

11.07
(26.1)
0.737

Doxorubicin

0.077

0.504

22

Tamoxifen

-

-

-

-

-

3.54
(8.3)

7.97
9.47

Rifampicin

0.025

Streptomycin

0.625

Mefloquine

(0.0303)

- = inactive.

the related indigo where the cascade process completely consumes the starting material after 1 h at 88
°C.2 Therefore, the indirubin molecule is more stable than indigo. The overall result of the cascade
allylation of indirubin is the unexpected one-pot production of spiroindolinepyrido[1,2-a]indoledione
heterocycles. This method provides simple access to these relatively complex structures with good
diastereoselectivity. Importantly, this chemistry provides a facile route to the spirooxindole skeleton, a

motif that is becoming increasingly important with the emergence of numerous examples both from
nature and with biological activity.36-38 The results reported here highlight this importance with examples
of derivatives which show significant activity as lead compounds against P. falciparum and micromolar
activity against 3 different cancer cell lines. Therefore, this new chemistry of indirubin presents fresh
possibilities to explore heterocyclic chemical space in a compact one-pot synthetic regime, which should
be amenable to further generalisation.
3.1. Experimental section
3.2. General Methods
DMF for dry reactions was obtained from a solvent purification system. Dichloromethane for extractions
and column chromatography was distilled in air prior to use or HPLC grade dichloromethane was used,
while other solvents were purchased reagent grade and used without further purification. Indirubin (2)
was synthesized according to a literature procedure from isatin and 3-iodo-(1H)-indole.10 Reactions were
carried out under nitrogen which was dried by passage through a 20 cm tube filled with CaCl2 or silica
based drying agent, unless otherwise stated. Solvents were removed in vacuo on a rotary evaporator and
products dried under high vacuum (~1 mbar) at room temperature. Flash column chromatography was
performed using Merck flash silica gel 60 (63-200 mesh), particle size 40-63 μm, under a positive
pressure of air. Preparative TLC (PTLC) was performed using Merck silica gel F254 pre-coated glass
plates (20 x 20 cm) with a layer thickness of 500, 1000, 1500 or 2000 μm.
Compounds were visualized under UV light (254 and 365 nm) using Merck silica gel F254 precoated
aluminium plates. Melting points (Mp) were determined using a Gallenkamp (Griffin) melting point
apparatus, are uncorrected and stated in degrees Celsius (°C). Infrared (IR) spectra were recorded with
neat samples using a Nicolet Avatar 360 FT-IR spectrometer fitted with a Smart Omni-Sampler
germanium crystal accessory. IR data is recorded in nanometers (nm) with peak intensity assigned as
weak (w), medium (m) or strong (s). Low resolution mass spectra were obtained by electrospray
ionisation (ESI) mass spectroscopy on a Micromass Platform LCZ spectrometer by injecting the samples
as a solution in methanol. In some cases 1% HCOOH was added to suppress dimerization and/or aid in
protonation. Alternatively, electron impact (EI) mass spectra were performed using a Shimadzu QP-5050
spectrometer. High resolution mass spectrometry (HRMS) was performed using electrospray ionisation
technique on a Waters QTOF Xevo spectrometer or electron impact technique on a Fison/VG AutospecTOF spectrometer at 70 eV with a source temperature of 250 °C. Ion mass charge (m/z) values of
molecular ions (M), fragment peaks and adducts are stated with their relative abundances in parentheses.
For compounds with more than one major isotope all significant isotopic peaks are reported. Proton (1H)
and carbon (13C) nuclear magnetic resonance (NMR) spectra were recorded at 500 and 125 MHz
respectively on a Varian Inova 500 MHz spectrometer or a VNMRS PS54 500 MHz spectrometer.
Alternatively, 1H and
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C NMR spectra were recorded at 300 and 75 MHz respectively on a Varian

Mercury 300 MHz spectrometer. All NMR shifts are reported in parts per million (ppm) and the δ values
reported relative to a standardised value (standard in brackets). NMR data was acquired in CDCl3 (TMS,
1

H: δ = 0 ppm; CDCl3, 13C: δ = 77.0 ppm), (CD3)2SO (DMSO, 1H: δ = 2.50 ppm; (CD3)2SO, 13C: δ = 39.5

ppm), CD3OD (methanol, 1H: δ = 3.31 ppm; CD3OD, 13C: δ = 49.0 ppm) and (CD3)2CO (acetone, 1H: δ =
2.05 ppm; (CD3)2CO, 13C: δ = 29.8 ppm). Coupling constants (J) are reported in Hertz (Hz) and refer to
coupling between hydrogen nuclei over three bonds if one coupling constant is reported. If two coupling
constants are reported, the smaller of the two refers to coupling between hydrogen nuclei over four bonds.
Multiplicities are reported as singlet (s), broad singlet (bs), doublet (d), doublet of doublet (dd), triplet (t),
doublet of triplet (dt), quartet (q), pentet (p), sextet, septet and multiplet (m). Assignment of carbons and
protons for all compounds are based on the 1D and 2D NMR spectroscopic experiments APT, gCOSY,
gHSQC, gHMBC and NOESY unless otherwise stated.
UV/Vis spectra were obtained on dichloromethane solutions using a double beam UV-Vis-NIR
spectrophotometer (Cary 500) operating between 300 – 1400 nm. All solutions were appropriately diluted
with dichloromethane prior to analysis to fit within the absorbance limits of the detector, and placed into
1 cm pathlength quartz cuvettes. All spectra were collected at room temperature. Sample sizes were
between 1.000-2.000 mg, weighed with an accuracy of 6 decimal places using the seven figure balance
CAHN C-35. Monosubstituted indirubin derivatives were diluted to 50.0 mL and all other indirubin
derivatives to 25.0 mL The ε values reported have the units M-1cm-1.
X-ray Structure Determination – images were measured on a Nonius Kappa CCD diffractometer
(MoKα, graphite monochromator, λ = 0.71073 Å) and data extracted using the DENZO package.39
Structure solution was by direct methods (SIR92).40 The structures were refined using the CRYSTALS
program package.41 Atomic coordinates, bond lengths and angles, and displacement parameters for
compounds 19, 20 and 21 have been deposited at the Cambridge Crystallographic Data Centre (CCDC
1048189-1048191). These data can be obtained free-of-charge via www.ccdc.cam.ac.uk/data_request/cif,
by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data
Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.
Computational Methods
Geometry Optimisations. The calculations were performed in vacuo throughout using the Spartan
package 2010 (V1.1.0) as the calculation tool and the geometry of the molecule in the ground state was
optimized using Hartree-Fock (HF) theory and the 6-31G* basis set.
UV/Vis spectra. The Spartan package 2010 (V1.1.0) was used as the tool to calculate the spectra of the
molecules in the ground state using either density functional theory and the hybrid functional B3LYP or
HF theory after geometry optimisation with the 6-31G* basis set.

3.3. Synthesis
Synthetic Note: All potentially chiral compounds in this work were isolated or used as racemates.
3.3.1. General Procedure A.
A suspension of indirubin (1.0 eq.) in anhydrous DMF (20 mL) was sonicated for 5 min. To the stirred
solution was added caesium carbonate (2.4 eq.) and the reaction mixture was heated to 70 °C. Allylic
bromide (or derivative) (2.9 eq.) was added and the reaction mixture was stirred for the specified time at
70 °C. The mixture was filtered while hot, washed with a little DMF and the filtrate concentrated under
reduced pressure. The crude residue was subjected to flash silica gel column chromatography (100%
petroleum spirit to CH2Cl2/petroleum spirit 4:1).
3.3.1.1. N'-Allylindirubin (9); N,N'-diallylindirubin (14); N-allylisatin (4).
Following the general procedure A, a suspension of indirubin (202 mg, 771 μmol) in DMF (20 mL) was
heated with caesium carbonate (603 mg, 1.85 mmol) and allyl bromide (193 μL, 2.24 mmol) for 16 h to
obtain N'-allylindirubin (9) (56.1 mg, 24%) as a red solid. Mp 177-179 °C. UV/Vis: λmax (ε) 535 (10184)
nm. IR [cm-1]: ν 3306 (NH, w), 1690 (w), 1654 (s), 1610 (s), 1463 (s), 1321(s), 1174 (s), 1103 (m), 1036
(m). 1H NMR [500 MHz]: δ 4.46 (2H, d, J = 5.5 Hz, H3''), 5.22 (1H, s, H1''a), 5.25 (1H, d, J = 5.0 Hz,
H1''b), 5.86-5.92 (1H, m, H2''), 6.86 (1H, d, J = 8.0 Hz, H7'), 6.96 (1H, d, J = 8.0 Hz, H7), 7.00 (1H, t, J =
8.0 Hz, H5), 7.12 (1H, t, J = 8.0 Hz, H5'), 7.28 (1H, t, J = 8.0 Hz, H6'), 7.49 (1H, t, J = 7.5 Hz, H6), 7.73
(1H, d, J = 7.5 Hz, H4), 8.89 (1H, d, J = 8.0 Hz, H4'), 10.53 (1H, s, NH). 13C NMR [125 MHz]: δ 42.4
(C3''), 106.6 (C3'), 108.8 (C7'), 112.1 (C7), 117.7 (C1''), 120.3 (C3a), 121.4 (C2), 121.8 (C5), 122.9 (C5'),
125.5 (C4), 125.8 (C4'), 129.4 (C6'), 131.7 (C2''), 137.1 (C6), 139.6 (C3'a), 141.4 (C7'a), 151.9 (C7a),
170.6 (C2'), 188.5 (C3). MS (EI): m/z 302 (M+, 100%). HRMS (ESI): calculated for C19H15N2O2:
303.1134, found 303.1143.
Further elution of the SiO2 flash column provided N,N'-diallylindirubin (14) (50.1 mg, 19%) as a blue
solid. Mp 82-84 °C. UV/Vis: λmax (ε) 577 (466042) nm. IR [cm-1]: ν 1670 (s), 1603 (s), 1461 (s), 1328 (s),
1173(s), 748.3 (s). 1H NMR [500 MHz]: δ 4.43 (2H, d, J = 5.0 Hz, H3''), 4.82 (2H, d, J = 6.0 Hz, H3'''),
5.19-5.23 (3H, m, H1''a, H1''b, H1'''a), 5.28 (1H, d, J = 10.0 Hz, H1'''b), 5.84-5.89 (1H, m, H2''), 5.94-5.97
(1H, m, H2'''), 6.82 (1H, d, J = 8.0 Hz, H7'), 7.02-7.09 (2H, m, H5, H5'), 7.12 (1H, d, J = 8.5 Hz, H7),
7.25 (1H, t, J = 7.5 Hz, H6'), 7.53 (1H, t, J = 7.5 Hz, H6), 7.72 (1H, d, J = 7.5 Hz, H4), 8.63 (1H, d, J =
7.5 Hz, H4'). 13C NMR [125 MHz]: δ 42.5 (C3''), 52.5 (C3'''), 108.7 (C7'), 110.9 (C3'), 112.5 (C7), 117.4
(C1''), 118.6 (C1'''), 121.8 (C3'a), 122.0 (C5'), 122.4 (C3a), 122.6 (C5), 125.0 (C4), 125.6 (C4'), 129.7
(C5'), 131.9 (C2''), 133.8 (C2'''), 136.6 (C6), 142.0 (C7'a), 142.4 (C2), 154.4 (C7a), 166.8 (C2'), 188.5
(C3). MS (EI): m/z 342 (M+, 100%), 301 (M+-C3H5, 52). MS (ESI): 343 (M+H+, 100%). HRMS (ESI):
calculated for C22H19N2O2: 343.1447, found 343.1425.

Further elution of the SiO2 flash column provided N-allylisatin (4) (29.0 mg, 10%) as an orange solid. Mp
87-88 ºC (Lit.1 89-91 °C). UV/Vis: λmax (ε) 410 (435) nm. IR [cm-1]: ν 2959 (w), 2919 (w), 2847 (w),
1722 (s), 1601 (s), 1464 (s), 1348 (m), 1183 (w), 1085 (w), 925 (w), 760 (s). 1H NMR [500 MHz]: δ 4.37
(2H, d, J = 5.5 Hz, H3'), 5.29-5.35 (2H, m, H1'), 5.82-5.88 (1H, m, H2'), 6.90 (1H, d, J = 8.0 Hz, H7),
7.13 (1H, t, J = 8.0 Hz, H5), 7.57 (1H, t, J = 8.0 Hz, H6), 7.62 (1H, d, J = 7.5 Hz, H4). 13C NMR [125
MHz]: δ 42.7 (C3'), 111.1 (C7), 117.8 (C3a), 118.9 (C1'), 124.0 (C5), 125.6 (C4), 130.6 (C2'), 138.5
(C6), 151.1 (C7a), 158.1 (C2), 183.5 (C3). MS (ESI): m/z 188 (M+H+, 100%).
3.3.1.2. 2-Methylallyl 2-((2-methylallyl)amino)benzoate; (Z)-1'-(2-Methylallyl)-[2,3'biindolinylidene] -2',3-dione (10); (Z)-1,1'-bis(2-methylallyl)-[2,3'-biindolinylidene] 2',3-dione (15); 1-allylindoline-2,3-dione (5).
Following the general procedure A, a suspension of indirubin (201 mg, 767 μmol) in DMF (20 mL) was
heated with caesium carbonate (600 mg, 1.84 mmol) and 3-bromo-2-methylpropene (224 μL, 2.22 mmol)
for 16 h to obtain 2-methylallyl 2-((2-methylallyl)amino)benzoate as a colourless oil (12.8 mg, 7%). IR
[cm-1]: ν 3371 (w), 2919 (m), 2845 (w), 1682 (s), 1222 (s). 1H NMR [500 MHz]: δ 1.79 (3H, s, H1''), 1.84
(3H, s, H1'''), 3.78 (2H, s, H3), 4.70 (s, 2H, H3'), 4.89 (1H, s, H1a), 4.98 (2H, s, H1a', H1b), 5.07 (1H, s,
H1b'), 6.59 (1H, t, J = 8.0 Hz, ArH3), 6.63 (1H, d, J = 8.5 Hz, ArH5), 7.33 (1H, t, J = 8.0 Hz, ArH4), 7.97
(1H, d, J = 8.0 Hz, ArH2). 13C NMR [125 MHz]: δ 19.8 (C1''), 20.6 (C1'''), 49.0 (C3), 67.6 (C3'), 110.0
(ArC1), 111.2 (C1''), 111.9 (ArC5), 112.8 (C1'''), 114.8 (ArC3), 131.7 (ArC2), 134.8 (ArC4), 140.5 (C2''),
142.0 (C2'''), 151.6 (ArC6), 166.2 (C=O). MS (EI) m/z: 245 (M+, 63), 172 (100%). HRMS (EI) m/z:
calculated for C15H19NO2: 245.1416; found 245.1415.
Further elution of the SiO2 flash column provided (Z)-1'-(2-methylallyl)-[2,3'-biindolinylidene]-2',3-dione
(10) (48.5 mg, 20%) as a red solid. Mp 154-156 °C. UV/Vis: λmax (ε) 536 (10339) nm. IR [cm-1]: ν 3314
(w), 2915 (w), 2845 (w), 1645 (s), 1604 (s), 1464 (s), 1316 (s), 1168 (s), 1082 (s). 1H NMR [500 MHz]: δ
1.76 (3H, s, H1'''), 4.38 (2Η, s, H3''), 4.87 (1H, s, H1''a), 4.95 (1H, s, H1''b), 6.86 (1H, d, J = 8.0 Hz, H7'),
6.96 (1H, d, J = 8.0 Hz, H7), 7.00 (1H, t, J = 7.0 Hz, H5), 7.12 (t, J = 8.0 Hz, H5'), 7.26 (1H, t, J = 8.0
Hz, H6'), 7.49 (1H, t, J = 7.5 Hz, H6), 7.72 (1H, d, J = 7.0 Hz, H4), 8.89 (1H, d, J = 7.5 Hz, H4'), 10.54
(1H, s, NH). 13C NMR [125 MHz]: δ 20.2 (C1'''), 46.0 (C3''), 106.6 (C3'), 109.0 (C7'), 112.1 (C7), 112.8
(C1''), 120.3 (C3a), 121.3 (C3'a), 121.8 (C5), 122.9 (C5'), 125.5 (C4), 125.7 (C4'), 129.4 (C6), 134.4
(C2), 137.1 (C6), 139.5 (C2''), 141.6 (C7'a), 151.9 (C7a), 170.8 (C2'), 188.5 (C3). MS (EI): m/z 316 (M+,
100%). HRMS (EI): calculated for C20H16N2O2: 316.1212, found 316.1218.
Further elution of the SiO2 flash column provided (Z)-1,1'-bis(2-methylallyl)-[2,3'-biindolinylidene]-2',3dione (15) (85.1 mg, 30%) as a blue solid. Mp 88-90 °C. UV/Vis: λmax (ε) 580 (4957) nm. IR [cm-1]: ν
1666 (s), 1596 (s), 1464 (s), 1324 (s), 1168 (s), 1078 (s), 741 (s). 1H NMR [500 MHz]: δ 1.50 (3H, s,
H1''''), 1.75 (3H, s, H1'''''), 4.35 (2H, s, H3'''), 4.81-4.91 (4H, m, H1''a, H1''b, H1'''a, H1'''b), 4.91 (2H, s,
H3''), 6.80 (1H, d, J = 7.5 Hz, H7'), 7.03-7.06 (2H, m, H5, H5'), 7.08 (1H, d, J = 8.5 Hz, H7), 7.23 (1H, t,

J = 7.5 Hz, H6'), 7.51 (1H, t, J = 8.0 Hz, H6), 7.72 (1H, d, J = 7.5 Hz, H4), 8.66 (1H, d, J = 8.0 Hz, H4').
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C NMR [125 MHz]: δ 19.9 (C1''''), 20.2 (C1'''''), 46.0 (C3''), 54.5 (C3'''), 108.8 (C7'), 111.0 (C3'), 112.3

(C1''), 112.5 (C7), 114.9 (C1'''), 121.5 (C3'a), 121.9 (C5'), 122.3 (C3a), 122.5 (C5), 125.1 (C4), 125.6
(C4'), 129.8 (C6'), 136.6 (C6), 139.1 (C2'''), 139.7 (C2''), 142.0 (C2), 142.3 (C7'a), 154.5 (C7a), 167.0
(C2'), 188.6 (C3). MS (EI): m/z 370 (M+, 100%). HRMS (EI): calculated for C24H22N2O2: 370.1681,
found 370.1686.
Further elution of the SiO2 flash column provided 1-(2-methylallyl)indoline-2,3-dione (5) (8.0 mg, 3%) as
an orange solid. Mp 87-88 ºC (Lit.3b Mp 87-88 °C). 1H NMR [500 MHz]: δ 1.77 (3H, s, H1''), 4.30 (2H, s,
H3'), 4.98 (2H, d, J = 19.5 Hz, H1'), 6.89 (1H, d, J = 8.0 Hz, H7), 7.12 (1H, t, J = 7.5 Hz, H5), 7.56 (1H,
t, J = 7.5 Hz, H6), 7.62 (1H, d, J = 7.5 Hz, H4).
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C NMR [125 MHz]: δ 20.1 (C1''), 46.3 (C3'), 111.3

(C7), 113.7 (C1'), 117.7 (C3a), 124.0 (C5), 125.5 (C4), 138.3 (C2'), 138.6 (C6), 151.3 (C7a), 158.3 (C2),
183.4 (C3). MS (EI): m/z 201 (M+, 100%).
3.3.1.3. (Z)-1'-(But-2-en-1-yl)-[2,3'-biindolinylidene] -2',3-dione (11); (Z)-1,1'-di(but2-en-1-yl)-[2,3'-biindolinylidene] -2',3-dione (16).
Following the general procedure A, a suspension of indirubin (201 mg, 767 μmol) in DMF (20 mL) was
heated with caesium carbonate (600 mg, 1.84 mmol) and crotyl bromide (229 μL, 2.22 mmol) for 16 h to
obtain (Z)-1'-(but-2-en-1-yl)-[2,3'-biindolinylidene]-2',3-dione (11) with a 2.3:1.0 ratio mixture of E:Z in
the N'-side chain (119 mg, 49 %) as a red solid. Mp 190-192 °C. UV/Vis: λmax (ε) 535 (10711) nm. IR
[cm-1]: ν 3306 (w), 2923 (w), 1646 (s), 1601 (s), 1459 (s), 1317 (s), 1165 (s), 1103 (s), 1072 (s), 743 (s).
1

H NMR [300 MHz]: δ 1.69 (3H, d, J = 6.0 Hz, H1''), 4.39 (2H, d, 5.5 Hz, H4''), 5.40-5.55 (1H, m, H3''),

5.69-5.77 (1H, m, H2''), 6.89 (1H, d, J = 7.8 Hz, H7'), 6.96-7.03 (2H, m, H5, H7), 7.13 (1H, t, J = 7.5 Hz,
H5'), 7.29 (1H, t, J = 8.0 Hz, H6'), 7.50 (1H, t, 7.4 Hz, H6), 7.73 (1H, d, J = 7.5 Hz, H4), 8.89 (1H, d, J =
8.1 Hz, H4'), 10.56 (1H, s, NH). 13C NMR [75 MHz]: δ 17.9 (C1''), 41.8 (C4''), 108.6 (C3), 108.9 (C7'),
112.2 (C7), 120.4 (C3'a), 121.5 (C3a), 121.9 (C5), 122.9 (C5'), 124.6 (C3''), 125.5 (C4), 125.8 (C4'),
128.7 (C2''), 129.4 (C6'), 137.2 (C6), 139.6 (C5), 141.6 (C3'a), 151.6 (C3a), 170.6 (C2'), 188.6 (C3). MS
(EI): m/z 316 (M+, 100%), 262 (M+-C4H6, 40). HRMS (ESI): calculated for C20H17N2O2: 317. 1290,
found 317.1303.
Further elution of the SiO2 flash column provided (Z)-1,1'-di(but-2-en-1-yl)-[2,3'-biindolinylidene]-2',3dione (16) with a 5.5:1.0 ratio mixture of E:Z in the N-side chain and a 2.0:1.0 ratio mixture of E:Z in the
N'-side chain (25.5 mg, 9%) as a blue solid. Mp 88-90 °C. IR [cm-1]: ν 2952 (w), 2914 (m), 2844 (w),
1705 (s), 1606 (s), 1467 (s), 1356 (m), 1176 (m), 1081 (m), 752 (s). 1H NMR [300 MHz]: δ 1.63-1.66
(6H, m, H1'', H1'''), 4.36 (2H, d, J = 5.7 Hz, H4''), 4.76 (2H, d, J = 6.0 Hz, H4'''), 5.41-5.74 (4H, m, H3'',
H3''', H2'', H2'''), 6.82 (1H, d, J = 8.7 Hz, H7'), 6.70-7.08 (2H, m, H5, H5'), 7.16 (1H, d, J = 8.1 Hz, H7),
7.25 (1H, t, J = 7.8 Hz, H6'), 7.52 (1H, t, J = 8.1 Hz, H6), 7.70 (1H, d, J = 7.5 Hz, H4), 8.62 (1H, d, J =
7.5 Hz, H4'). 13C NMR [75 MHz]: δ 17.9 (H1'''), 18.1 (H1''), 41.9 (H4'''), 52.0 (H4''), 108.7 (C7'), 110.9

(C3), 112.7 (C7), 121.8 (C5'), 122.0 (C3a), 122.48 (C5'), 122.53 (C3'a), 124.8 (C4), 125.0 (C3''), 125.7
(H4'), 126.3 (C3'''), 126.4 (C2'''), 129.7 (C6'), 130.4 (C2''), 136.6 (C6), 142.2 (C7'a), 142.5 (C2), 154.6
(C7a), 166.8 (C2'), 188.7 (C3'). MS (EI): m/z 370 (M+, 100%), 315 (M+-C4H7, 56). HRMS (ESI):
calculated for C24H23N2O2: 371.1760, found 371.1744.
3.3.1.4. (Z)-1'-(3-Methylbut-2-en-1-yl)-[2,3'-biindolinylidene] -2',3-dione (12); (Z)1,1'-bis(3-methylbut-2-en-1-yl)-[2,3'-biindolinylidene] -2',3-dione (17).
Following the general procedure A, a suspension of indirubin (209 mg, 798 μmol) in DMF (20 mL) was
heated with caesium carbonate (624 mg, 1.91 mmol) and 3,3-dimethylallyl bromide (267 μL, 2.31 mmol)
for 16 h to obtain (Z)-1'-(3-methylbut-2-en-1-yl)-[2,3'-biindolinylidene]-2',3-dione (12) as a red solid
(76.4 mg, 29%). Mp 184-186 °C. UV/Vis: λmax (ε) 535 (10777) nm. IR [cm-1]: ν 3316 (w), 2920 (w),
1641 (s), 1600 (s), 1464 (s), 1350 (s), 1318 (s), 1166 (s), 1068 (s), 1036 (s), 742 (s). 1H NMR [300 MHz]:
δ 1.73 (3H, s, H1''), 1.86 (3H, s, H1'''), 4.41 (2H, d, J = 6.3 Hz, H4''), 5.22 (1H, t, J = 6.6 Hz, H3''), 6.83
(1H, d, J = 8.1 Hz, H7'), 6.93-7.00 (2H, m, H5, H7), 7.10 (1H, t, J = 7.5 Hz, H5'), 7.47 (1H, t, J = 7.2 Hz,
H6), 7.71 (1H, d, J = 7.5 Hz, H4), 8.86 (1H, d, J = 7.5 Hz, H4'), 10.53 (1H, s, NH). 13C NMR [75 MHz]:
δ 18.5 (C1''), 26.0 (C1'''), 38.2 (C4''), 107.1 (C3'), 108.7 (C7'), 112.2 (C7), 118.8 (C2''), 120.4 (C3a),
121.6 (C3'a), 121.8 (C5), 122.8 (C5'), 125.5 (C4), 125.9 (C4'), 129.4 (C6'), 137.0 (C2''), 137.2 (C6), 139.6
(C2), 141.7 (C7'a), 152.0 (C7a), 170.5 (C2'), 188.6 (C3). MS (EI): m/z 330 (M+, 80), 262 (M+-C5H8,
100%). HRMS (ESI): calculated for C21H19N2O2: 331.1447, found 331.1425.
Further elution of the SiO2 flash column provided (Z)-1,1'-bis(3-methylbut-2-en-1-yl)-[2,3'biindolinylidene]-2',3-dione (17) (9.53 mg, 3%) as a blue solid. Mp: 92-94 °C. UV/Vis: λmax (ε) 578
(5892) nm. IR [cm-1]: ν 2958 (w), 2917 (m), 2875 (w), 1673 (s), 1603 (s), 1460 (s), 1325 (s), 1163 (s),
1071 (s), 742 (s). 1H NMR [500 MHz]: δ 1.66 (3H, s, H1'''), 1.70 (3H, s, H1'''''), 1.71 (3H, s, H1''), 1.84
(3H, s, H1''''), 4.41 (2H, d, J = 7.0 Hz, H4''), 4.82 (2H, d, J = 6.0 Hz, H4'''), 5.18-5.24 (2H, m, H3'', H3'''),
6.90 (1H, d, J = 7.5 Hz, H7'), 7.02-7.06 (3H, m, H5, H5', H7), 7.25 (1H, t, J = 7.5 Hz, H6'), 7.51 (1H, t, J
= 7.0 Hz, H6), 7.70 (1H, d, J = 7.0 Hz, H4), 8.61 (1H, d, J = 7.5 Hz, H4'). 13C NMR [125 MHz]: δ 18.4
(C1'''), 18.5 (CH3'''), 25.8 (C1''), 25.9 (CH3''), 38.3 (C4'''), 48.1 (C4''), 108.5 (C7'), 108.7 (C3'), 112.5 (C7),
119.1 (C3''), 120.2 (C3'''), 121.8 (C5'), 122.0 (C3'a), 122.4 (C5), 122.6 (C3a), 124.9 (C4), 125.6 (C4'),
129.6 (C6'), 136.4 (C2'''), 136.5 (C6), 136.6 (C2''), 142.1 (C7'a), 142.6 (C2), 154.5 (C7a), 166.6 (C2'),
188.9 (C3). MS (EI): m/z 398 (M+, 90), 329 (M+-C5H9, 57), 262 (M+-C10H16, 100%). HRMS (ESI):
calculated for C26H27N2O2: 399.2073, found 399.2060.
3.3.1.5. (Z)-1'-Cinnamyl-[2,3'-biindolinylidene] -2',3-dione (13).
Following the general procedure A, a suspension of indirubin (204 mg, 779 μmol) in DMF (20 mL) was
heated with caesium carbonate (609 mg, 1.87 mmol) and cinnamyl bromide (450 mg, 2.26 mmol) for 16
h to obtain (Z)-1'-cinnamyl-[2,3'-biindolinylidene]-2',3-dione (13) (61.8 mg, 21%) as a red solid. Mp 180182 °C. UV/Vis: λmax (ε) 535 (10159) nm. IR [cm-1]: ν 3303 (w), 2920 (w), 2847 (w), 1638 (s), 1600 (s),

1464 (s), 1356 (s), 1315 (s), 1169 (s), 1074 (s), 742 (s). 1H NMR [300 MHz]: δ 4.58 (2H, d, J = 5.7 Hz,
H3''), 6.22 (1H, dt, J = 15.9 Hz, J = 5.7 Hz, H2''), 6.59 (1H, d, J = 15.9 Hz, H1''), 6.87-6.99 (3H, m, H5,
H7, H7'), 7.09 (1H, t, J = 7.8 Hz, H5'), 7.20-7.32 (6H, m, ArH2, ArH3, ArH4, ArH5, ArH6, H6'), 7.45
(1H, t, J = 7.5 Hz, H6), 7.69 (1H, d, J = 7.2 Hz, H7'), 8.86 (1H, d, J = 7.5 Hz, H4'), 10.51 (1H, s, NH).
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C NMR [75 MHz]: δ 42.1 (H3''), 106.8 (C3'), 108.9 (C7), 112.2 (C7'), 120.4 (C3a), 121.5 (C3'a), 121.9

(C5), 123.0 (C2''), 123.3 (C5'), 125.6 (C4), 125.9 (C4'), 126.8 (ArC2, ArC6), 128.2 (C6'), 128.9 (ArC3,
ArC5), 129.5 (Ar4), 133.1 (C1''), 136.5 (ArC1), 137.2 (C6), 139.7 (C2), 141.4 (C7'a), 151.9 (C7a), 170.7
(C2'), 188.5 (C3). MS (EI): m/z 378 (M+, 86), 263 (M+-C9H7, 100%). HRMS (ESI): calculated for
C25H19N2O2: 379.1447, found 379.1454.
3.3.1.6. (Z)-1,1'-Dicinnamyl-[2,3'-biindolinylidene] -2',3-dione (18).
Following the general procedure A, a suspension of indirubin (201 mg, 767 μmol) in DMF (20 mL) was
heated with caesium carbonate (600 mg, 1.84 mmol) and cinnamyl bromide (443 mg, 2.22 mmol) for 4 h
to obtain (Z)-1,1'-dicinnamyl-[2,3'-biindolinylidene]-2',3-dione (18) with a 1.0:1.1 ratio mixture of E:Z in
the N-side chain and a 1.0:1.5 ratio mixture of E:Z in the N'-side chain (41.7 mg, 11%) as a blue solid. Mp
89-93 °C. IR [cm-1]: ν 2917 (m), 1673 (s), 1603 (s), 1464 (s), 1325 (m), 1173 (s), 1084 (s), 739 (s). 1H
NMR [300 MHz]: δ 2.81 (2H, d, J = 7.2 Hz, H3'') 4.61 (2H, d, J = 6.0 Hz, H3'''), 6.21 (1H, dt, J = 15.9
Hz, 5.7 Hz, H2''), 6.36 (1H, dt, J = 15.9 Hz, 5.7 Hz, H2'''), 6.59 (1H, d, J = 15.9 Hz, H1''), 6.63 (1H, d, J =
16.2 Hz, H1'''), 6.88 (1H, d, J = 7.8 Hz, H7'), 7.04 (1H, t, J = 8.1 Hz, H5'), 7.10-7.32 (12H, m, ArH2,
ArH2', ArH3, ArH3', ArH4, ArH4', ArH5, ArH5', ArH6, ArH6', H6', H7), 7.49 (1H, t, J = 7.8 Hz, H6),
7.73 (1H, d, J = 7.8 Hz, H4), 8.65 (1H, d, J = 8.1 Hz, H4'). 13C NMR [75 MHz]: δ 40.8 (C3''), 42.2 (C3'''),
108.9 (C7'), 111.0 (ArC), 112.7 (ArC), 121.9 (ArC), 122.1 (C5), 122.5 (ArC), 122.8 (C5'), 123.5 (C2'''),
123.7 (C2''), 124.1 (ArC), 125.1 (C4), 125.8 (C4''), 126.5 (2 x ArC), 126.6 (ArC), 126.76 (2 x ArC),
127.5 (ArC), 128.3 (ArC), 128.8 (2 x ArC), 129.9 (ArC), 131.4 (ArC), 132.8 (ArC), 134.1 (ArC), 136.8
(C6), 142.1 (ArC), 143.1 (C7'a), 154.5 (C7a), 166.9 (C2), 178.8 (C2'), 188.6 (C3). MS (EI): m/z 494 (M+,
40), 377 (M+-C9H9, 33), 362 (M+-C10H12, 100%). HRMS (ESI): calculated for C34H27N2O2: 495.2073,
found 495.2080.
3.3.1.7. Prop-2-yn-1-yl 2-(prop-2-yn-1-ylamino)benzoate; (Z)-1,1'-di(prop-2-yn-1-yl)[2,3'-biindolinylidene] -2',3-dione.
Following the general procedure A, a suspension of indirubin (205 mg, 767 μmol) in DMF (20 mL) was
heated with caesium carbonate (600 mg, 1.84 mmol) and propargyl bromide (443 mg, 2.22 mmol) for 16
h to obtain prop-2-yn-1-yl 2-(prop-2-yn-1-ylamino)benzoate (13.2 mg, 8%) as a colourless solid. Mp 5354 ºC (Lit.5a 55-56 °C). 1H NMR [300 MHz]: δ 2.24 (1H, t, J = 2.7 Hz, H1''), 2.50 (1H, t, J = 2.7 Hz,
H1'), 4.04 (2H, dd, J = 5.9 Hz, 2.4 Hz, H3''), 4.87 (2H, d, J = 2.4 Hz, H3'), 6.69 (1H, td, J = 7.5 Hz, 0.6
Hz, H5), 6.80 (1H, d, J = 8.4 Hz, H3), 7.43 (1H, td, J = 8.0 Hz, 1.5 Hz, H4), 7.85 (1H, bs, NH), 7.97 (1H,
dd, J = 8.1 Hz, 1.8 Hz, H6). 13C NMR [75 MHz]: δ 32.7 (C3''), 52.2 (C3'), 71.6 (C1''), 75.0 (C1'), 78.2

(C2'), 79.8 (C2''), 110.4 (C1), 111.9 (C3), 116.1 (C5), 132.1 (C6), 135.3 (C4), 150.4 (C2), 167.8 (C=O).
MS (ESI), m/z 214 (M+H+, 100%). HRMS (ESI): calculated for C13H12NO2: 214.0868, found 214.0860.
Further elution of the SiO2 flash column provided (Z)-1,1'-di(prop-2-yn-1-yl)-[2,3'-biindolinylidene]-2',3dione (33.8 mg, 13%) as a blue solid. Mp 183-185 °C. UV/Vis: λmax (ε) 559 (4292) nm. IR [cm-1]: ν 3261
(w), 3234 (w), 1650 (s), 1606 (s), 1464 (s), 1330 (s), 1165 (s), 1076 (s), 1019 (m), 930 (m), 756 (s). 1H
NMR [500 MHz]: δ 2.24 (1H, t, J = 2.0 Hz, H1''), 2.27 (1H, t, J = 2.0 Hz, H1'''), 4.62 (2H, d, J = 2.5 Hz,
H3''), 5.02 (2H, d, J = 2.5 Hz, H3'''), 7.05 (1H, d, J = 8.0 Hz, H7'), 7.09-7.15 (2H, m, H5, H5'), 7.27 (1H,
d, J = 8.0 Hz, H7), 7.34 (1H, t, J = 7.5 Hz, H6'), 7.61 (1H, t, J = 8.0 Hz, H6), 7.75 (1H, d, J = 7.0 Hz,
H4), 8.70 (1H, d, J = 8.0 Hz, H4').
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C NMR [125 MHz]: δ 29.5 (C3''), 39.5 (C3'''), 72.3 (C1''), 74.0

(C1'''), 77.2 (C2''), 77.3 (C2'''), 108.9 (C7'),111.5 (C7'a), 112.6 (C7), 122.05 (C3'), 122.07 (C3'a), 122.6
(C5), 123.1 (C5'), 125.1 (C4), 126.3 (C4'), 130.3 (C6'), 136.8 (C6), 141.2 (C7'a), 142.2 (C2), 153.7 (C7a),
166.3 (C2'), 188.0 (C3). MS (EI): m/z 338 (M+, 100%), 299 (M+-C3H3, 78). HRMS (ESI): calculated for
C22H15N2O2: 339.1134, found 339.1127.
3.3.2. General Procedure B.
A suspension of indirubin (1.0 eq.) in dry DMF (20 mL for 763 μmol) was sonicated for 5 min and then 3
Ǻ molecular sieves (40.0 g for 763 μmol) were added. To the stirred solution was added caesium
carbonate (2.4 eq.) and the reaction mixture was flushed with N2 and heated to 70 °C. The allyl bromide
or an analogous derivative (4.7 eq.) was added and the reaction mixture was heated to 110 °C and stirred
at this temperature for 6-24 h under an atmosphere of N2. The mixture was filtered while hot, washed
with a little DMF and the filtrate concentrated under reduced pressure. The crude residue was subjected to
flash silica gel column chromatography (gradient to CH2Cl2/petroleum spirit 4:1).
3.3.2.1. Allyl 2-(allylamino)benzoate; 1,9a'-Diallyl-8'H-spiro[indoline-3,9'-pyrido[1,2a] indole] -2,10'(9a'H)-dione (19).
Following the general procedure B, a suspension of indirubin (206 mg, 786 μmol) in DMF (20 mL) was
heated with caesium carbonate (615 mg, 1.89 mmol) and allyl bromide (319 μL, 3.69 mmol) for 6 h to
obtain allyl 2-(allylamino)benzoate as a colourless oil (11.6 mg, 7%). IR [cm-1]: ν 3364 (w), 3266 (m),
2914 (w), 2848 (w), 1673 (m), 1232 (s), 1103 (s). 1H NMR [500 MHz]: δ 3.87 (2H, t, J = 5.5 Hz, H3),
4.78 (2H, d, J = 6.0 Hz, H3'), 5.18 (1H, d, J = 10.5 Hz, H1a), 5.27 (1H, d, J = 9.0 Hz, H1b), 5.29 (1H, d, J
= 15.3 Hz, H1a'), 5.40 (1H, d, J = 17.5 Hz, H1b'), 5.91-5.99 (1H, m, H2), 5.99-6.06 (1H, m, H2'), 6.59
(1H, t, J = 7.5 Hz, ArH3), 6.66 (1H, d, J = 8.5 Hz, ArH5), 7.34 (1H, t, J = 7.8 Hz, ArH4), 7.86 (1H, bs,
NH), 7.96 (1H, d, J = 8.0 Hz, ArH2). 13C NMR [125 MHz]: δ 45.5 (C3), 65.1 (C3'), 111.8 (ArC1), 114.9
(ArC5), 116.3 (C1), 118.0 (C1'), 131.9 (ArC5), 132.8 (C2'), 134.5 (C2), 134.8 (ArC4), 151.3 (ArC6),
168.5 (C=O). MS (ESI) m/z: 217 (M+H+, 100%). HRMS (ESI) m/z: calculated for C13H16NO2: 218.1181;
found 218.1181.

Further elution of the silica gel flash column provided 1,9a'-diallyl-8'H-spiro[indoline-3,9'-pyrido[1,2a]indole]-2,10'(9a'H)-dione (19) (210 mg, 70%) as a yellow solid. Mp 189-191 °C. UV/Vis: λmax (ε) 414
(2014). IR [cm-1]: ν 1699 (s), 1605 (s), 1472 (m), 1361 (w), 1197 (w), 752 (s). 1H NMR [300 MHz]: δ
2.06 (1Η, ddd, J = 18.3 Hz, 5.3 Hz, 1.8 Hz, H8'a), 2.74 (1H, dd, J = 13.7 Hz, 7.2 Hz, H3'''a), 3.00 (1H, dt,
J = 18.3 Hz, 1.8 Hz, H8'b), 3.33 (1H, dd, J = 14.1 Hz, 6.9 Hz, H3'''b), 4.33 (1H, ddt, J = 15.9 Hz, 5.4 Hz,
3.6 Hz, H3''a), 4.54-4.61 (1H, m, H3''b), 4.83 (1H, dd, J = 9.9 Hz, 2.4 Hz, H1'''a), 5.05 (1H, dd, J = 16.8
Hz, 1.8 Hz, H1'''b), 5.02-5.41 (4H, m, H1''a, H1''b, H2''', H7'), 5.88-6.11 (1H, m, H2''), 6.57 (1H, t, J = 7.5
Hz, H5), 6.68 (1H, t, J = 8.3 Hz, H2'), 6.74 (1H, d, J = 7.5 Hz, H7), 6.83 (1H, d, J = 7.2 Hz, H4), 7.007.06 (3H, m, H6, H6', H4'), 7.24 (1H, d, J = 8.1 Hz, H1'), 7.45 (1H, t, J = 8.4 Hz, H3').
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C NMR [75

MHz]: δ 30.1 (C8'), 35.0 (C3'''), 42.8 (C3''), 48.0 (C3), 70.4 (C9'a), 103.3 (C1''), 107.8 (C4'), 108.9 (C7),
117.5 (C2'''), 119.2 (C2'), 119.4 (C1'''), 121.8 (C5), 122.0 (C10'a), 122.5 (C6'), 124.3 (C1'), 124.7 (C4),
128.2 (C6), 128.9 (C3a), 131.0 (C7'), 131.6 (C2''), 137.3 (C3'), 142.1 (C7a), 156.1 (C4'a), 175.6 (C2),
199.1 (C10'). MS (EI): m/z 382 (M+, 74), 341 (M+-C3H5, 100%), 300 (M+-C6H10, 51). HRMS (ESI):
calculated for C25H23N2O2: 383.1760, found 383.1751.
3.3.2.2. 7'-Methyl-1,9a'-bis(2-methylallyl)-8'H-spiro[indoline-3,9'-pyrido[1,2a] indole] -2,10'(9a'H)-dione (20).
Following the general procedure B, a suspension of indirubin (205 mg, 782 μmol) in DMF (20 mL) was
heated with caesium carbonate (612 mg, 1.88 mmol) and 3-bromo-2-methylpropene (370 μL, 3.68 mmol)
for

6

h

to

obtain

7'-methyl-1,9a'-bis(2-methylallyl)-8'H-spiro[indoline-3,9'-pyrido[1,2-a]indole]-

2,10'(9a'H)-dione (20) (123 mg, 37%) as a yellow solid. Mp 212-214 °C. UV/Vis: λmax (ε) 435 (2274) nm.
IR [cm-1]: ν 2969 (w), 2923 (w), 1690 (s), 1600 (s), 1476 (s), 1349 (m), 745 (s). 1H NMR [500 MHz]: δ
1.51 (3H, s, H1''''''), 1.85 (3H, s, H1''''), 1.89 (3H, s, H1'''''), 1.89 (1H, d, J = 18.0 Hz, H8'a), 2.68 (1H, d, J
= 13.5 Hz, H3'''a), 2.98 (1H, d, J = 18.0 Hz, H8'b), 3.29 (1H, d, J = 14.0 Hz, H3'''b), 4.32 (1H, d, J = 16.0
Hz, H3''a), 4.41 (1H, d, J = 16.0 Hz, H3''b), 4.59 (1H, s, H1'''a), 4.61 (1H, s, H1'''b), 4.97 (1H, s, H1''a), 5.02
(1H, s, H1''b), 6.54 (1H, t, J = 7.5 Hz, H5), 6.60 (1H, t, J = 7.5 Hz, H2'), 6.74 (1H, d, J = 8.0 Hz, H7),
6.78 (1H, d, J = 8.0 Hz, H4), 6.79 (1H, s, H6'), 6.95 (1H, d, J = 8.5 Hz, H4'), 7.01 (1H, t, J = 8.0 Hz, H6),
7.20 (d, J = 7.5 Hz, H1'), 7.41 (1H, t, J = 7.0 Hz, H3'). 13C NMR [125 MHz]: δ 20.3 (C1''''), 20.4 (C1'''''),
24.3 (C1''''''), 36.0 (C8'), 38.4 (C3'''), 46.8 (C3''), 49.0 (C3), 70.5 (C9'a), 107.8 (C4'), 109.3 (C7), 112.8
(C1''), 113.2 (C7'), 116.2 (C1'''), 117.8 (C4), 118.8 (C2'), 122.1 (C5), 122.7 (C10'a), 124.5 (C1'), 124.9
(C6'), 128.4 (C6), 129.3 (C3a), 137.4 (C3'), 139.4 (C2''), 139.8 (C2'''), 142.7 (C7a), 156.7 (C4'a), 176.1
(C2), 199.6 (C10'). MS (EI): m/z 424 (M+, 30), 369 (M+-C4H7, 100%). HRMS (EI): calculated for
C28H28N2O2: 424.2151, found 424.2150.
3.3.2.3. (E)-1-(But-2-en-1-yl)-9a'-(but-3-en-2-yl)-8'-methyl-8'H-spiro[indoline-3,9'pyrido[1,2-a] indole]-2,10'(9a'H)-dione (21).

Following the general procedure B, a suspension of indirubin (202 mg, 771 μmol) in DMF (20 mL) was
heated with caesium carbonate (603 mg, 1.85 mmol) and crotyl bromide (373 μL, 3.62 mmol) for 6 h to
obtain a fraction that was further purified by PTLC providing a mixture of at least two stereoisomers
(arising from the cis/trans mixture in the double bond of the crotyl bromide starting material) of 1-(but-2en-1-yl)-9a'-(but-3-en-2-yl)-8'-methyl-8'H-spiro[indoline-3,9'-pyrido[1,2-a]indole]-2,10'(9a'H)-dione (21)
(78.5 mg, 24%) as a yellow solid. Mp 154-160 °C. UV/Vis: λmax (ε) 411 (2211) nm. IR [cm-1]: ν 1691 (s),
1606 (s), 1470 (m), 1363 (w), 1337 (w), 748 (s). 1H NMR [300 MHz]: δ 0.52 (3H, d, J = 8.0 Hz, H1''''),
1.53 (3H, d, J = 7.3 Hz, H1'''''), 1.72 (3H, d, J = 7.3 Hz, H1''), 3.40-3.47 (2H, m, H8', H3'''), 4.33-4.46
(2H, m, H4''), 4.64 (1H, dd, J = 10.0 Hz, 1.8 Hz, H1'''a), 4.86 (1H, dd, J = 17.0 Hz, 2.1 Hz, H1'''b), 5.03
(1H, dd, J = 8.9 Hz, 2.3 Hz, H7'), 5.35-5.48 (1H, m, H2'''), 5.51-5.57 (1H, m, H3''), 5.72-5.89 (1H, m,
H2''), 6.48 (1H, t, J = 8.3 Hz, H5), 6.57 (1H, d, J = 7.8 Hz, H4), 6.67-6.76 (2H, m, H2', H4'), 7.01 (1H, t,
J = 8.3 Hz, H6), 7.08-7.16 (3H, m, H1', H6', H7), 7.45 (1H, t, J = 7.8 Hz, H3'). 13C NMR [75 MHz]: δ
15.6 (C1'''), 17.9 (C1''''), 18.0 (C1''), 34.6 (C8'), 42.6 (C4''), 43.3 (C3'''), 53.7 (C3), 73.6 (C9'a), 109.07
(C6'), 109.12 (C4'), 110.9 (C7'), 116.0 (C1'''), 120.1 (C2'), 121.5 (C5), 123.9 (C10'a), 124.5 (C1'), 124.9
(C3''), 125.2 (C7), 125.7 (C4), 127.2 (C3'a), 128.2 (C6), 129.3 (C2''), 136.8 (C3'), 139.6 (C2'''), 143.6
(C7a), 157.5 (C4'a), 175.9 (C2), 200.0 (ArC10'). MS (EI): m/z 424 (M+, 26), 369 (M+-C4H7, 75), 315
(M+-C4H6, 100%). HRMS (ESI): calculated for C28H29N2O2: 425.2229, found 425.2237.
3.3.2.4. 1,9a'-Dicinnamyl-8'-phenyl-8'H-spiro[indoline-3,9'-pyrido[1,2-a] indole] 2,10'(9a'H)-dione (22); 1-cinnamylindoline-2,3-dione (8).
Following the general procedure B, a suspension of indirubin (205 mg, 782 μmol) in DMF (20 mL) was
heated with caesium carbonate (612 mg, 1.88 mmol) and cinnamyl bromide (731 mg, 3.68 mmol) for 24
h to obtain a fraction that was further purified by PLC providing two products, the first of which was
1,9a'-dicinnamyl-8'-phenyl-8'H-spiro[indoline-3,9'-pyrido[1,2-a]indole]-2,10'(9a'H)-dione (22) (39.2 mg,
8%), obtained as a yellow solid. Mp 118-120 °C. UV/Vis: λmax (ε) 414 (165942) nm. IR [cm-1]: ν 1701(s),
1606 (s), 1470 (s), 1340 (w), 962 (w), 745 (s) 1H NMR [300 MHz]: δ 3.17 (1H, ddd, J = 14.1 Hz, 7.8 Hz,
1.2 Hz, H3'''a), 3.71 (1H, ddd, J = 13.5 Hz, 7.2 Hz, 1.2 Hz, H3'''b), 4.23 (1H, ddd, J = 16.4, 5.7 Hz, 1.8 Hz,
H3''a), 4.52-4.61 (2H, m, H3''b, H8'), 5.30 (1H, dd, J = 8.0 Hz, 2.1 Hz, H7'), 5.74-5.85 (2H, m, H2''', H2''),
6.23 (1H, d, J = 16.2 Hz, H1'''), 6.45-6.54 (1H, m, H1''), 6.68 (1H, t, J = 7.2 Hz, H2'), 6.87 (1H, t, J = 6.6
Hz, H5), 6.9-7.30 (21H, m, ArH2, ArH3, ArH4, ArH5, ArH6, ArH2', ArH3', ArH4', ArH5', ArH6',
ArH2'', ArH3'', ArH4'', ArH5'', ArH6'', H1', H4', H6', H4, H6, H7), 7.46 (1H, t, J = 7.7 Hz, H3'). 13C NMR
[75 MHz]: δ 34.8 (C3'''), 42.3 (C3''), 45.2 (C8'), 53.7 (C3), 72.3 (C9'a), 107.8 (C7'), 108.3 (C1''), 109.1
(C1'''), 119.9 (C5), 121.6 (C1''), 123.0 (ArC), 123.3 (C2'''), 123.4 (C2''), 123.5 (ArC), 124.9 (ArC), 125.7
(ArC), 126.39 (2 x ArC), 126.44 (ArC), 126.7 (ArC), 126.8 (2 x ArC), 127.3 (ArC), 127.7 (2 x ArC),
127.8 (ArC), 128.5 (ArC), 128.6 (2 x ArC), 128.7 (2 x ArC), 128.8 (ArC), 129.9 (2 x ArC), 132.3 (ArC),
134.7 (ArC), 136.8 (ArC), 137.7 (ArC), 138.0 (ArC1), 142.9 (C7a), 156.1 (C4a), 175.2 (C2), 199.4

(C10'). MS (EI): m/z 610 (M+, 90%), 493 (M+-C9H9, 100%), 375 (M+-C18H19, 40%). MS (ESI): m/z 611
(M+H+, 100%). HRMS (ESI): calculated for C43H35N2O2: 611.2699, found 611.2681.
The second product separated from the above PTLC procedure was 1-cinnamylindoline-2,3-dione (8)
(17.7 mg, 9%), obtained as an orange solid. Mp 108-110 °C. UV/Vis: λmax (ε) 424 (569) nm. IR [cm-1]: ν
1726 (s), 1601 (s), 1464 (m), 1366 (m), 1343 (m), 1165 (m), 762 (s). 1H NMR [300 MHz]: δ 4.53 (2H, d,
J = 5.7 Hz, H3'), 6.18 (1H, dt, J = 5.7 Hz, J = 16.2 Hz, H2'), 6.68 (1H, d, J = 16.2 Hz, H1'), 6.96 (1H, d, J
= 7.8 Hz, H7), 7.12 (1H, t, J = 7.8 Hz, H5), 7.25-7.37 (5H, m, ArH2, ArH3, ArH4, ArH5, ArH6), 7.56
(1H, t, J = 7.8 Hz, H6), 7.62 (1H, d, J = 7.5 Hz, H4). 13C NMR [75 MHz]: δ 42.5 (C3'), 111.2 (C7), 118.0
(C3a), 121.8 (C2'), 124.1 (C5), 125.7 (C7), 126.8 (ArC3, ArC5), 128.5 (ArC4), 129.0 (ArC2, ArC6),
134.4 (C1'), 136.0 (ArC1), 138.7 (C6), 151.1 (C7a), 158.2 (C2), 183.6 (C3). MS (EI): m/z 263 (M+,
100%). HRMS (ESI): calculated for C17H14NO2: 264.1025, found 264.1012.
3.3.2.5. Attempted allylation starting from N1'-allylindirubin.
Following general procedure B, N1'-indirubin (9) (97.1 mg, 321 μmol) in DMF (8 mL) was heated with
caesium carbonate (126 mg, 385 μmol) and allyl bromide (74.3 μL, 770 μmol) was added before being
stirred for 20 h. Workup of the reaction produced an indefinable mixture of compounds with only the
corresponding N-allylisatin detected by TLC analysis.
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